

**TRANSCENE BIOTECH LIMITED**  
**68,69,&70, ANRICH INDUSTRIAL AREA**  
**BOLLARAM, MEDAK RURAL AREA**  
**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2011**

PARTICULARS	3 Months Ended	3 Months ended	Half Year Ended	Half Year Ended	For the year Ended
	30.09.2011	30.09.2010	30.09.2011 Unaudited	30.09.2010 Unaudited	31.03.2011 Audited
	Rs.		Rs.	Rs.	Rs.
1. Net Sales/Income from operations	641.01		75.80	1,240.37	173.76
2. Other Income	2.25		-	7.15	4.54
<b>3. Total Income (1+2)</b>	<b>643.26</b>		<b>75.80</b>	<b>1,247.52</b>	<b>173.76</b>
4. Expenditure					
a. Increase/ decrease in stock in trade and work in progress					
b. Consumption of raw materials	2.41		-	7.22	12.80
c. purchase of traded goods	498.89		-	1,003.69	-
d. Employees cost	19.35		9.51	35.88	16.62
e. Depreciation	9.48		8.43	18.37	16.81
f. Other expenditure	45.97		36.26	83.48	78.84
h. Total	576.10		54.20	1,148.64	125.07
Earnings before Interest and Tax	67.16		21.60	98.88	64.30
5. Interest	17.57		16.63	33.34	33.58
6. Exceptional items-forex fluctuation( gain)/Loss	(903.33)		-	(918.37)	-
<b>7. Profit(+)/ Loss(-) from ordinary Activities before tax (3) - (4+5+6)</b>	<b>952.93</b>		<b>4.97</b>	<b>983.92</b>	<b>950.07</b>
8. Tax expense	9.45		0.89	12.41	2.72
<b>9. Net Profit (+)/Loss (-) from ordinary Activities After Tax (7-8)</b>	<b>943.48</b>		<b>4.08</b>	<b>971.50</b>	<b>12.39</b>
10. Extraordinary items ( net of tax expenses Rs. _____ )	-			-	
<b>11. Net Profit (+) / Loss(-) for the period (9-10)</b>	<b>943.48</b>		<b>4.08</b>	<b>971.50</b>	<b>12.39</b>
12. Paid -up equity share capital(Face value - Rs.10/-)	4,077.00		1577.00	4077.00	1577.00
13. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	17,477.66			17,477.66	17,477.66
14. Earning per share (EPS)					
a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.12		0.03	0.16	0.08
b) Basic and diluted EPS after Extraordinary items for the period, for the previous year (not to be annualized)	2.31		0.03	2.38	0.08
15. Public Share holding					
Number of shares	34,334,361		296361	34,334,361	9296361
Percentage of shareholding	84.21		58.95	84.21	58.95

*[Handwritten Signature]*

16. Promoters and Promoter Group Share holding					
<b>Pledged / Encumbered</b>					
Number of shares	-	335000	-	335000	330,500.00
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	5.17	-	5.17	5.11
Percentage of shares (as a % of the total share capital of the company)	-	2.12	-	2.12	0.81
<b>Non-Encumbered</b>					
Number of Shares	6,435,639.00	6138639	6435639	6138639	6,137,639.00
Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	94.83	100.00	94.83	94.89
Percentage of shares (as a % of the total share capital of the company)	15.79	38.93	15.79	38.93	15.05

*[Handwritten Signature]*

**Annexure IV to Cl**  
**Format for Reporting of Segment wise Revenue, Results and**

**e 41**  
**Capital Employed along with the quarterly results**  
**(Rs. In Lakhs)**

S.No	PARTICULARS	Quarter	Quarter	Half	Half	For the year
		Ended	Ended	Year	Year	Ended
		30.09.2011	30.09.2010	30.09.11	30.09.10	31.03.2011
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>SEGMENT REVENUE</b>					
	a)Segment -A Diagnostic Services	39.57	75.80	61.69	150.30	299.21
	b)Segment -B Agri Division	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	601.44	-	1,178.68	23.46	649.34
	<b>Total:</b>	<b>641.01</b>	<b>75.80</b>	<b>1,240.37</b>	<b>173.76</b>	<b>948.55</b>
	Less: Inter Segment Revenue					
	<b>Net Sales/income From Operation</b>	<b>641.01</b>	<b>75.80</b>	<b>1,240.37</b>	<b>173.76</b>	<b>948.55</b>
2	<b>SEGMENT RESULTS</b>					
	(Profit /Loss Before Tax & Interest from each Segment)					
	a)Segment -A Diagnostic services	11.28	21.60	17.58	42.84	94.95
	b)Segment -B Agri Division	-	-	-	-	-
	c) Segment-C Bulk Drugs Trading	53.63	-	71.29	5.85	134.63
	<b>Total Segmental Result</b>	<b>64.91</b>	<b>21.603</b>	<b>88.87</b>	<b>48.6855</b>	<b>229.58</b>
	Other Income	<b>2.25</b>		<b>7.15</b>		<b>4.54</b>
	<b>Total</b>	<b>67.16</b>	<b>21.60</b>	<b>96.02</b>	<b>48.69</b>	<b>234.12</b>
	Less: Interest & Finance Charges	17.57	16.63	33.34	33.58	71.47
	Less: Unallocable expenses					29.81
	Exceptional items-forex fluctuation(gain)/Loss	(903.33)	-	(918.37)		116.05
	<b>Total Profit/Loss Before Tax</b>	<b>952.93</b>	<b>4.97</b>	<b>981.06</b>	<b>15.11</b>	<b>16.79</b>
3	<b>CAPITAL EMPLOYED</b>					
	a)Segment - A Diagnostic services	324.83	281.41	324.83	281.41	324.83
	b)Segment - B Agri Division					
	c) Segment-C Bulk Drugs	24,090.93	1,329.42	24,090.93	11,329.42	23,198.78
	<b>Total</b>	<b>24,415.76</b>	<b>1,610.83</b>	<b>24,415.76</b>	<b>11,610.83</b>	<b>23,523.61</b>

## Notes :

- 1) We have commenced the commercial production of DHA, as scheduled, during the early part of October, 11.
- 2) With the commencement of DHA being successfully implemented, the management is now focusing at the commercial production of another API, Tacrolimus, at the company's own facility.
- 3) As reported earlier, the management is seeking to establish strategic partnerships with some parties in Europe and North America to cater to the regulated and developing country markets.
- 4) We are in advanced stage for concluding the technology sale on the line of the bio-generics.
- 5) All the R&D projects including various novel drugs against Breast cancer, Colon cancer etc in addition to the novel drug for HIV and MS, are advancing rapidly on the expected lines.
- 6) In-vivo animal efficacy studies, which are highly complex, on two cancer drugs are in progress.
- 7) Exceptional Item of Rs.903.33 lakhs represents gain due to Foreign Exchange Fluctuations.
- 8) The company has issued 2500000 GDRs representing 25000000 Indian Rupee Shares of Rs.10/- each @ USD 7 per GDRs and the same were allotted on 3rd October 2011.
- 9) No. of Investor complaints pending at the beginning of the quarter - Nil; resolved during the quarter - NIL; pending unresolved at the end of the quarter - NIL.
- 10) The above results were reviewed by the Audit Committee and the Board of Directors of the company at their meeting held on November 15, 2011.

Place : Hyderabad


Date : 15<sup>th</sup> November 2011

D KOTESWARA RAO  
C CHAIRMAN & MANAGING DIRECTOR

## ANNEXURE IX TO CLAUSE 1

Particulars	6 Months ended	6 Months ended
	(30/09/2011)	(30/09/2010)
	Unaudited	Unaudited
(Rs. In Lakhs)		
<b>SHAREHOLDERS FUND:</b>		
(a) Capital	4,077.00	1577
(b) Reserve & Surplus	18,447.93	10033.1
<b>LOAN FUNDS</b>	<b>2,065.37</b>	<b>1722.27</b>
<b>TOTAL:</b>	<b>24,590.30</b>	<b>13332.37</b>
<b>FIXED ASSETS</b>	<b>21,298.53</b>	<b>10618.67</b>
<b>INVESTMENTS</b>	<b>0.35</b>	
<b>CURRENT ASSETS, LOANS AND ADVANCES</b>		
(a) Inventories	70.70	1.52
(b) Sundry Debtors	1,745.21	82.1
(c) Cash and Bank Balances	142.90	10.61
(d) Other Current assets		
(e) Loans and Advances	121.69	168.95
A	2,080.50	263.18
<b>Less: Current Liabilities and Provisions</b>		
(a) Liabilities	1,709.27	95.93
(b) Provisions	41.00	37.34
B	1,750.27	133.27
<b>NET CURRENT ASSETS(A-B)</b>	<b>330.23</b>	<b>129.91</b>
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	2,961.19	2583.79
<b>PROFIT AND LOSS ACCOUNT</b>		
<b>TOTAL:</b>	<b>24,590.30</b>	<b>13332.37</b>

For and on behalf of the Board of Directors



Dr.K.Koteswara Rao  
Chairman & Managing Director

Place: Hyderabad

Date : 15-11-2011